<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937519</url>
  </required_header>
  <id_info>
    <org_study_id>2016080201</org_study_id>
    <nct_id>NCT02937519</nct_id>
  </id_info>
  <brief_title>Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer</brief_title>
  <official_title>Multi-center Phase II Clinical Randomized Study of Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guiyang Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guiyang Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Observe and compare the chrono-chemotherapy IMRT and conventional chemotherapy and
           intensity modulated radiotherapy term efficacy of the treatment of locally advanced
           nasopharyngeal carcinoma.

        2. Evaluation chrono-chemotherapy IMRT and conventional chemotherapy and intensity
           modulated radiotherapy in locally advanced nasopharyngeal carcinoma safety and
           tolerability.

      3）observing the adverse reaction and effects of two groups,expected chrono-chemotherapy group
      can achieve lower toxicity, improve the curative effect, for the treatment of nasopharyngeal
      carcinoma provides a more reasonable way.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with curative effect</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the immediate effect at 1year after Concurrent chemo-radiotherapy by RECIST.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>5 years</time_frame>
    <description>To assess and record nausea, vomiting, oral mucositis, diarrhea and other adverse drug reactions by CTC 3.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate the Progression-free survival at five years after Concurrent chemo-radiotherapy by RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate the Overall survival at five years after Concurrent chemo-radiotherapy by RECIST.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Esophageal Neoplasms [C06.405.117.430]</condition>
  <arm_group>
    <arm_group_label>Melodie group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine-Chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chrono-chemotherapy pump:Melodie</intervention_name>
    <arm_group_label>Melodie group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Routine intravenous drip</intervention_name>
    <arm_group_label>Routine-Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction Chrono-chemotherapy</intervention_name>
    <arm_group_label>Melodie group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction Routine-chemotherapy</intervention_name>
    <arm_group_label>Routine-Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin chrono-chemotherapy</intervention_name>
    <arm_group_label>Melodie group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin routine-chemotherapy</intervention_name>
    <arm_group_label>Routine-Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <arm_group_label>Melodie group</arm_group_label>
    <arm_group_label>Routine-Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  initial treatment of advanced nasopharyngeal carcinoma Ⅲ-Ⅳ patients with
             pathologically confirmed (according to 2010 UICC staging, T3-4, N0-3), without
             evidence of distant metastasis (M0). Have measurable tumor lesions.

          -  KPS≥70 points.

          -  the age of 18-70 years old, male or female.

          -  no major organ dysfunction; normal bone marrow function (WBC ≥4.0 × 109 / L, platelets
             ≥100 × 109 / L, hemoglobin ≥90g / L), normal liver function (total bilirubin, alanine
             aminotransferase, aspartate aminotransferase ≤1.5 times the upper limit of normal),
             normal renal function (creatinine ≤ 1.5 times upper limit of normal).

          -  understand this study and signed informed consent.

        Exclusion Criteria:

          -  distant metastasis.

          -  who had received prior chemotherapy.

          -  patients have physical or mental illness, and by researchers believe that patients can
             not be completely or fully understood in this study possible complications.

          -  pregnancy (via the urine or serum β-HCG test confirmed) or during lactation.

          -  serious complications, such as uncontrolled hypertension, heart failure, diabetes and
             so on.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hang Jiang, Bachelor degree</last_name>
    <phone>0851-86512802</phone>
    <email>233956010@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Jin, Bachelor</last_name>
      <phone>0851-86512802</phone>
      <email>jinf8865@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Feng Jin, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ling Guo, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ling Wu, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weili Wu, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinhua Long, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuanyuan Li, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiuyun Gong, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoxiao Chen, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhuoling Li, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hang Jiang, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>October 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>October 16, 2016</last_update_submitted>
  <last_update_submitted_qc>October 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guiyang Medical University</investigator_affiliation>
    <investigator_full_name>Feng Jing</investigator_full_name>
    <investigator_title>Chief physician/Professor</investigator_title>
  </responsible_party>
  <keyword>Chronomodulated Chemotherapy</keyword>
  <keyword>Intensity Modulated Radiation Therapy</keyword>
  <keyword>Advanced Nasopharyngeal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

